FDA Oncology Adcomm Votes To Keep Conditional Approval For Roche's Tecentriq In Place For Now
The FDA kicked off a three-day meet to reexamine the accelerated approvals of immuno-oncology drugs with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals.
